Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients

  • STATUS
    Recruiting
  • End date
    Jun 30, 2024
  • participants needed
    144
  • sponsor
    Lifetech Scientific (Shenzhen) Co., Ltd.
Updated on 22 January 2021

Summary

The aim of this study is to evaluate the safety and efficacy of Absnow absorbable ASD closure system for treating patients with atrial septal defect.

Description

Atrial Septal Defect (hereinafter referred to as "ASD") is a common congenital heart disease (hereinafter referred to as "CHD"), accounting for about 10% of CHD in children.InitiallyASD was treated by surgical operation. Nowdays transcatheter ASD closure, characterized by minimal invasion, definite curative effect, short recovery period, and no need for cardiopulmonary bypass, provides a new safe and effective therapy for CHD. According to a large number of clinical reports, the use of transcatheter closure devices for ASD closure has a high success rate, good closure effect and low risk of complications.

Absnow absorbable ASD closure system has undergone implantation experiments that implant it into animal (pig) ASD models, with the implantation success rate being 100%. Up to 2 years' observation indicated that the cardiomyocytes and endothelial cells covering the implanted device were not different from those of the control group (nickel-titanium alloy occluder) and were of a great number, and the inflammatory response was remarkably lower than that of the control group. During the observation period, all occluders in the trial did not fall off or were displaced, no evident postoperative complications and therefore, this occluder has the feasibility of local application and system safety.

Absnow absorbable ASD closure system developed by LifeTech Scientific passed the registration inspection of CFDA Shenzhen Medical Device Quality Monitoring and Inspection Center, verifying that this closure system conforms to the product technical specification in mechanical strength, physiochemical properties and biological properties. According to the provisions in Measures for Administration of Medical Device Registration (No. 4 Order) and Regulation on Quality Management of Medical Device Clinical Trial (No. 25) issued by CFDA, this product has the conditions for clinical trial.

Details
Condition Atrial septal defect, atrial septal defects, atrial septal defect (asd)
Treatment Absnow Absorbable ASD Closure System
Clinical Study IdentifierNCT03601039
SponsorLifetech Scientific (Shenzhen) Co., Ltd.
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 3 , weight 10Kg
Secundum left-to-right shunt ASD with hemodynamic significance
Distance from the defect edge to coronary vein sinus, superior and inferior vena cava, pulmonary vein5mm and AV valve should be 7mm
The atrial septum length (stretched diameter) should be greater than the diameter of left disk

Exclusion Criteria

Patients of primum, venous sinus and coronary sinus ASD
Patients with atrial septum defect 26mm
Patients with other structural heart disease in addition to ASD
Patients with complication of obstructive pulmonary arterial hypertension, Eisenmenger syndrome
Infective endocarditis patients
Patients with hemolysis or hemorrhagic disease, unhealed ulcer or any taboo about aspirin (except being able to take other anti-platelet agent for consecutive six months) within one month before implantation
Patients with thrombosis(especially in left atrium or left atrial appendage thrombus) as shown by echocardiography
Patients with known condition of hypercoagulation status
Patients ever received heart operation
Patients allergic to PLLA
Patients refusing to sign the informed consent form
Patients with poor compliance on treatment and poor cooperation on follow-up visits
Patients that are in pregnancy or lactation, or planned for pregnancy or get a positive pregnancy test result during the screening period
Patients that have participated in any clinical trial that may affect the evaluation of the device in this trial and not completed or withdrawn from the previous clinical trial within 3 months prior to this trial screening period
The patients considered to be not eligible for this clinical trial by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note